Literature DB >> 8549411

Initial clinical experience with clinafloxacin in the treatment of serious infections.

K J Tack1, N M McGuire, I A Eiseman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549411     DOI： 10.2165/00003495-199500492-00145

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  2 in total

1.  Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

Authors:  P C Fuchs; A L Barry; M A Pfaller; S D Allen; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.

Authors:  R N Jones; D M Johnson
Journal:  Diagn Microbiol Infect Dis       Date:  1995-04       Impact factor: 2.803
  2 in total
  5 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Authors:  G Siami; N Christou; I Eiseman; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

4.  In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.

Authors:  R C Mercier; S R Penzak; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.

Authors:  Akshu Balwan; David P Nicolau; Minkey Wungwattana; Jonathan B Zuckerman; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2015-12-31       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.